LynxKite’s graph-analytics workloads ran on Nebius while the product was part of Lynx Analytics. LynxKite became a separate product company on 1 March 2026 and named Nebius as a strategic partner. Biophytis describes LynxKite supplying large-scale GPU computing through cloud infrastructure including Nebius for MASSIVE, their drug-discovery project targeting the Mas receptor and sarcopenia. Planned objectives include receptor modeling, AI-guided molecule generation and predictive screening, with laboratory feedback used to develop and validate the software. Further plans include synthesizing and evaluating MasR activators for biological activity, safety and pharmacokinetics, selecting and patenting a lead candidate for preclinical development, and expanding the platform to other modalities. Biophytis’s March 2026 announcement explicitly identifies Nebius AI Cloud as powering their joint longevity drug-discovery development. Lynx Analytics describes the Biophytis partnership as multi-year, supported by an EUREKA–Enterprise Singapore grant to further develop LynxKite’s AI and computational biology capabilities.
At GTC 2026, LynxKite presented the approach with Biophytis, Nebius and Accenture, using BIO101 and the Mas receptor as a reference case. Biophytis also describes a live demonstration at the Nebius booth featuring that receptor and drug candidate. LynxKite reported that integrated platform, data and computing workflows were bringing early discovery timelines from about 24 months to 6–8 months. Nebius also named LynxKite and Biophytis among teams running AI workloads on its infrastructure.
LynxKite describes its platform as combining graph analytics and biological language models while managing, optimizing and autoscaling GPU resources for pipelines such as NVIDIA NIM Microservices. Its expanded Biophytis partnership plans include a computational longevity platform with curated datasets and accelerated computation methods, and drug candidates for dry age-related macular degeneration.
Nebius Lynx Analytics: historical LynxKite workloads7 Dec 2025 · Nebius · Web pageThe Nebius customer story describes LynxKite graph-AI workloads during its time within Lynx Analytics.
Biophytis et LynxKite renforcent leur alliance IA X
12 Mar 2026 · www.biophytis.com · Web page
Biophytis describes LynxKite providing large-scale GPU computing on cloud infrastructure including Nebius for their MASSIVE drug-discovery collaboration. Planned objectives include Mas receptor modeling, AI-guided molecule generation and predictive screening. Plans also include synthesizing and evaluating MasR activators for biological activity, safety and pharmacokinetics, selecting and patenting a lead candidate for preclinical development, and expanding the platform to other modalities.
Biophytis et LynxKite renforcent leur alliance IA X12 Mar 2026 · www.biophytis.com · Web pageBiophytis describes LynxKite providing large-scale GPU computing on cloud infrastructure including Nebius for their MASSIVE drug-discovery collaboration. Planned objectives include Mas receptor modeling, AI-guided molecule generation and predictive screening. Plans also include synthesizing and evaluating MasR activators for biological activity, safety and pharmacokinetics, selecting and patenting a lead candidate for preclinical development, and expanding the platform to other modalities.
BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY – Biophytis X
26 Mar 2026 · www.biophytis.com · Web page
Biophytis describes joint longevity drug-discovery development with LynxKite powered by Nebius AI Cloud. It also describes a live demonstration at the Nebius booth featuring the MAS receptor and BIO101.
BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY – Biophytis X26 Mar 2026 · www.biophytis.com · Web pageBiophytis describes joint longevity drug-discovery development with LynxKite powered by Nebius AI Cloud. It also describes a live demonstration at the Nebius booth featuring the MAS receptor and BIO101.
Lynx Analytics and LynxKite Separate into Independent Companies | Lynx Analytics posted on the topic | LinkedIn
5 Mar 2026 · www.linkedin.com · Web page
Lynx Analytics announces LynxKite’s independence from 1 March 2026 and names Nebius as a strategic partner. It describes a multi-year Biophytis drug-discovery partnership supported by an EUREKA–Enterprise Singapore grant.
Lynx Analytics and LynxKite Separate into Independent Companies | Lynx Analytics posted on the topic | LinkedIn5 Mar 2026 · www.linkedin.com · Web pageLynx Analytics announces LynxKite’s independence from 1 March 2026 and names Nebius as a strategic partner. It describes a multi-year Biophytis drug-discovery partnership supported by an EUREKA–Enterprise Singapore grant.
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
19 Oct 2026 · lynxkite.com · Web page
LynxKite describes scaling GPU computation using neoclouds including Nebius for its MASSIVE collaboration with Biophytis. It also describes its platform combining graph analytics and biological language models with GPU resource management and autoscaling for pipelines such as NVIDIA NIM Microservices. Partnership plans include curated longevity datasets, accelerated computation methods and drug candidates for dry age-related macular degeneration.
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics19 Oct 2026 · lynxkite.com · Web pageLynxKite describes scaling GPU computation using neoclouds including Nebius for its MASSIVE collaboration with Biophytis. It also describes its platform combining graph analytics and biological language models with GPU resource management and autoscaling for pipelines such as NVIDIA NIM Microservices. Partnership plans include curated longevity datasets, accelerated computation methods and drug candidates for dry age-related macular degeneration.
LynxKite develops graph analytics and AI software for life sciences companies and research teams working on drug discovery. Its platform combines biomedical knowledge graphs, machine learning, molecular analysis and GPU computing to identify targets, generate and screen compounds, and prioritize drug candidates. Its main offerings are the open-source LynxKite 2000:MM platform and a commercial Enterprise edition with cluster deployment and dedicated support. Biophytis uses LynxKite in its MASSIVE longevity drug-discovery project. LynxKite became an independent product company in March 2026.
LynxKite and Hummingbird Bioscience develop toxicity knowledge graph
Hummingbird Bioscience disclosed a collaboration with LynxKite to build an explainable toxicity knowledge graph using NVIDIA accelerated computing. Hummingbird supplies biological expertise and datasets, while LynxKite contributes graph software, data curation, analytics and model development.
LynxKite introduces Inference Microservices for GPU model deployment
LynxKite introduced Inference Microservices, which deploy Python model functions as Kubernetes services and handle scaling within its workflows. The announcement demonstrates ESMFold2 integration and offers the capability through LynxKite Enterprise.
LynxKite’s graph-analytics workloads ran on Nebius while the product was part of Lynx Analytics. LynxKite became a separate product company on 1 March 2026 and named Nebius as a strategic partner. Biophytis describes LynxKite supplying large-scale GPU computing through cloud infrastructure including Nebius for MASSIVE, their drug-discovery project targeting the Mas receptor and sarcopenia. Planned objectives include receptor modeling, AI-guided molecule generation and predictive screening, with laboratory feedback used to develop and validate the software. Further plans include synthesizing and evaluating MasR activators for biological activity, safety and pharmacokinetics, selecting and patenting a lead candidate for preclinical development, and expanding the platform to other modalities. Biophytis’s March 2026 announcement explicitly identifies Nebius AI Cloud as powering their joint longevity drug-discovery development. Lynx Analytics describes the Biophytis partnership as multi-year, supported by an EUREKA–Enterprise Singapore grant to further develop LynxKite’s AI and computational biology capabilities.
At GTC 2026, LynxKite presented the approach with Biophytis, Nebius and Accenture, using BIO101 and the Mas receptor as a reference case. Biophytis also describes a live demonstration at the Nebius booth featuring that receptor and drug candidate. LynxKite reported that integrated platform, data and computing workflows were bringing early discovery timelines from about 24 months to 6–8 months. Nebius also named LynxKite and Biophytis among teams running AI workloads on its infrastructure.
LynxKite describes its platform as combining graph analytics and biological language models while managing, optimizing and autoscaling GPU resources for pipelines such as NVIDIA NIM Microservices. Its expanded Biophytis partnership plans include a computational longevity platform with curated datasets and accelerated computation methods, and drug candidates for dry age-related macular degeneration.
Nebius Lynx Analytics: historical LynxKite workloads7 Dec 2025 · Nebius · Web pageThe Nebius customer story describes LynxKite graph-AI workloads during its time within Lynx Analytics.
Biophytis et LynxKite renforcent leur alliance IA X
12 Mar 2026 · www.biophytis.com · Web page
Biophytis describes LynxKite providing large-scale GPU computing on cloud infrastructure including Nebius for their MASSIVE drug-discovery collaboration. Planned objectives include Mas receptor modeling, AI-guided molecule generation and predictive screening. Plans also include synthesizing and evaluating MasR activators for biological activity, safety and pharmacokinetics, selecting and patenting a lead candidate for preclinical development, and expanding the platform to other modalities.
Biophytis et LynxKite renforcent leur alliance IA X12 Mar 2026 · www.biophytis.com · Web pageBiophytis describes LynxKite providing large-scale GPU computing on cloud infrastructure including Nebius for their MASSIVE drug-discovery collaboration. Planned objectives include Mas receptor modeling, AI-guided molecule generation and predictive screening. Plans also include synthesizing and evaluating MasR activators for biological activity, safety and pharmacokinetics, selecting and patenting a lead candidate for preclinical development, and expanding the platform to other modalities.
BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY – Biophytis X
26 Mar 2026 · www.biophytis.com · Web page
Biophytis describes joint longevity drug-discovery development with LynxKite powered by Nebius AI Cloud. It also describes a live demonstration at the Nebius booth featuring the MAS receptor and BIO101.
BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY – Biophytis X26 Mar 2026 · www.biophytis.com · Web pageBiophytis describes joint longevity drug-discovery development with LynxKite powered by Nebius AI Cloud. It also describes a live demonstration at the Nebius booth featuring the MAS receptor and BIO101.
Lynx Analytics and LynxKite Separate into Independent Companies | Lynx Analytics posted on the topic | LinkedIn
5 Mar 2026 · www.linkedin.com · Web page
Lynx Analytics announces LynxKite’s independence from 1 March 2026 and names Nebius as a strategic partner. It describes a multi-year Biophytis drug-discovery partnership supported by an EUREKA–Enterprise Singapore grant.
Lynx Analytics and LynxKite Separate into Independent Companies | Lynx Analytics posted on the topic | LinkedIn5 Mar 2026 · www.linkedin.com · Web pageLynx Analytics announces LynxKite’s independence from 1 March 2026 and names Nebius as a strategic partner. It describes a multi-year Biophytis drug-discovery partnership supported by an EUREKA–Enterprise Singapore grant.
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
19 Oct 2026 · lynxkite.com · Web page
LynxKite describes scaling GPU computation using neoclouds including Nebius for its MASSIVE collaboration with Biophytis. It also describes its platform combining graph analytics and biological language models with GPU resource management and autoscaling for pipelines such as NVIDIA NIM Microservices. Partnership plans include curated longevity datasets, accelerated computation methods and drug candidates for dry age-related macular degeneration.
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics19 Oct 2026 · lynxkite.com · Web pageLynxKite describes scaling GPU computation using neoclouds including Nebius for its MASSIVE collaboration with Biophytis. It also describes its platform combining graph analytics and biological language models with GPU resource management and autoscaling for pipelines such as NVIDIA NIM Microservices. Partnership plans include curated longevity datasets, accelerated computation methods and drug candidates for dry age-related macular degeneration.
LynxKite develops graph analytics and AI software for life sciences companies and research teams working on drug discovery. Its platform combines biomedical knowledge graphs, machine learning, molecular analysis and GPU computing to identify targets, generate and screen compounds, and prioritize drug candidates. Its main offerings are the open-source LynxKite 2000:MM platform and a commercial Enterprise edition with cluster deployment and dedicated support. Biophytis uses LynxKite in its MASSIVE longevity drug-discovery project. LynxKite became an independent product company in March 2026.
LynxKite and Hummingbird Bioscience develop toxicity knowledge graph
Hummingbird Bioscience disclosed a collaboration with LynxKite to build an explainable toxicity knowledge graph using NVIDIA accelerated computing. Hummingbird supplies biological expertise and datasets, while LynxKite contributes graph software, data curation, analytics and model development.
LynxKite introduces Inference Microservices for GPU model deployment
LynxKite introduced Inference Microservices, which deploy Python model functions as Kubernetes services and handle scaling within its workflows. The announcement demonstrates ESMFold2 integration and offers the capability through LynxKite Enterprise.
